Shopping Cart 0
Cart Subtotal
USD 0

LEO Pharma AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

LEO Pharma A/S (LEO Pharma), a subsidiary of LEO Foundation is a research-based pharmaceutical company. It discovers, develops, manufactures and commercializes pharmaceuticals in therapeutic areas dermatology and thrombosis. The company focuses on the treatment of diseases such as psoriasis, eczema, skin infections, actinic keratosis and non-melanoma skin cancer, besides thrombosis. It also manufactures and markets products for the treatment of diseases in the areas of cardiovascular, bacterial infections, coagulation, osteoporosis and renal care. LEO Pharma markets its products worldwide and has presence in countries across Europe, the Middle East, Africa, Asia, North America, Central America, South America and Oceania. LEO Pharma is headquartered in Ballerup, Denmark.

LEO Pharma AS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LEO Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 13

LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 15

Partnerships 16

Leo Pharma Enters into Licensing Agreement with Klox Technologies 16

HitGen Enters into Research Agreement with LEO Pharma 17

LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 18

Klox Technologies and LEO Pharma to Form Joint Venture 19

MorphoSys Expands Agreement with LEO Pharma 20

LEO Pharma Enters into Agreement with Washington University School of Medicine 21

Leo Pharma Enters into Distribution Agreement with NeoPharm 22

arGEN-X Enters into Co-Development Agreement with Leo Pharma 23

Fidelta Enters into Drug Discovery Agreement with LEO Pharma 24

Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 25

LEO Pharma And University of Queensland Enter Into Research Agreement For Skin Cancer 26

LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 27

LEO Pharma To Enter Into Joint Venture With Charite To Form I2DEAL 28

Licensing Agreements 29

Zymeworks Enters into Research Collaboration and Licensing Agreement with LEO Pharma 29

LEO Pharma Enters into Licensing Agreement with JW Pharma 30

UTILITY therapeutics Enters into Licensing Agreement with LEO Pharma 31

LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 32

LEO Pharma Enters Into Licensing Agreement With AstraZeneca For Brodalumab 33

Leo Pharma Enters into Licensing Agreement with Japan Tobacco for JTE-052 34

LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 35

Equity Offering 36

LEO Pharma Invests in Novopyxis 36

Asset Transactions 37

Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 37

Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 39

LEO Pharma A/S-Key Competitors 40

LEO Pharma A/S-Key Employees 41

LEO Pharma A/S-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 45

Financial Announcements 45

Mar 02, 2018: A record year for LEO Pharma 45

Apr 03, 2017: LEO Pharma 2016 result surpassed expectations 47

Corporate Communications 49

Aug 28, 2018: LEO Pharma appointed Olivier Bohuon as Board Director 49

May 28, 2018: LEO Pharma Names Christian Antoni as Senior Vice President for Global Development, R&D 50

Mar 20, 2018: LEO Pharma Appoints Rhonda Duffy To Lead Global Product Supply 51

Jun 23, 2017: LEO Pharma Appoints Chris Posner to Lead US Business 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

LEO Pharma A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LEO Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LEO Pharma A/S, Deals By Therapy Area, 2012 to YTD 2018 9

LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 13

LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 15

Leo Pharma Enters into Licensing Agreement with Klox Technologies 16

HitGen Enters into Research Agreement with LEO Pharma 17

LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 18

Klox Technologies and LEO Pharma to Form Joint Venture 19

MorphoSys Expands Agreement with LEO Pharma 20

LEO Pharma Enters into Agreement with Washington University School of Medicine 21

Leo Pharma Enters into Distribution Agreement with NeoPharm 22

arGEN-X Enters into Co-Development Agreement with Leo Pharma 23

Fidelta Enters into Drug Discovery Agreement with LEO Pharma 24

Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 25

LEO Pharma And University of Queensland Enter Into Research Agreement For Skin Cancer 26

LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 27

LEO Pharma To Enter Into Joint Venture With Charite To Form I2DEAL 28

Zymeworks Enters into Research Collaboration and Licensing Agreement with LEO Pharma 29

LEO Pharma Enters into Licensing Agreement with JW Pharma 30

UTILITY therapeutics Enters into Licensing Agreement with LEO Pharma 31

LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 32

LEO Pharma Enters Into Licensing Agreement With AstraZeneca For Brodalumab 33

Leo Pharma Enters into Licensing Agreement with Japan Tobacco for JTE-052 34

LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 35

LEO Pharma Invests in Novopyxis 36

Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 37

Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 39

LEO Pharma A/S, Key Competitors 40

LEO Pharma A/S, Key Employees 41

LEO Pharma A/S, Subsidiaries 42

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

LEO Pharma A/S (LEO Pharma), a subsidiary of LEO Foundation is a research-based pharmaceutical company. It discovers, develops, manufactures and commercializes pharmaceuticals in therapeutic areas dermatology and thrombosis. The company focuses on the treatment of diseases such as psoriasis, eczema, skin infections, actinic keratosis and non-melanoma skin cancer, besides thrombosis. It also manufactures and markets products for the treatment of diseases in the areas of cardiovascular, bacterial infections, coagulation, osteoporosis and renal care. LEO Pharma markets its products worldwide and has presence in countries across Europe, the Middle East, Africa, Asia, North America, Central America, South America and Oceania. LEO Pharma is headquartered in Ballerup, Denmark.

LEO Pharma AS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LEO Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 13

LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 15

Partnerships 16

Leo Pharma Enters into Licensing Agreement with Klox Technologies 16

HitGen Enters into Research Agreement with LEO Pharma 17

LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 18

Klox Technologies and LEO Pharma to Form Joint Venture 19

MorphoSys Expands Agreement with LEO Pharma 20

LEO Pharma Enters into Agreement with Washington University School of Medicine 21

Leo Pharma Enters into Distribution Agreement with NeoPharm 22

arGEN-X Enters into Co-Development Agreement with Leo Pharma 23

Fidelta Enters into Drug Discovery Agreement with LEO Pharma 24

Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 25

LEO Pharma And University of Queensland Enter Into Research Agreement For Skin Cancer 26

LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 27

LEO Pharma To Enter Into Joint Venture With Charite To Form I2DEAL 28

Licensing Agreements 29

Zymeworks Enters into Research Collaboration and Licensing Agreement with LEO Pharma 29

LEO Pharma Enters into Licensing Agreement with JW Pharma 30

UTILITY therapeutics Enters into Licensing Agreement with LEO Pharma 31

LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 32

LEO Pharma Enters Into Licensing Agreement With AstraZeneca For Brodalumab 33

Leo Pharma Enters into Licensing Agreement with Japan Tobacco for JTE-052 34

LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 35

Equity Offering 36

LEO Pharma Invests in Novopyxis 36

Asset Transactions 37

Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 37

Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 39

LEO Pharma A/S-Key Competitors 40

LEO Pharma A/S-Key Employees 41

LEO Pharma A/S-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 45

Financial Announcements 45

Mar 02, 2018: A record year for LEO Pharma 45

Apr 03, 2017: LEO Pharma 2016 result surpassed expectations 47

Corporate Communications 49

Aug 28, 2018: LEO Pharma appointed Olivier Bohuon as Board Director 49

May 28, 2018: LEO Pharma Names Christian Antoni as Senior Vice President for Global Development, R&D 50

Mar 20, 2018: LEO Pharma Appoints Rhonda Duffy To Lead Global Product Supply 51

Jun 23, 2017: LEO Pharma Appoints Chris Posner to Lead US Business 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

LEO Pharma A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

LEO Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

LEO Pharma A/S, Deals By Therapy Area, 2012 to YTD 2018 9

LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10

LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 13

LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 15

Leo Pharma Enters into Licensing Agreement with Klox Technologies 16

HitGen Enters into Research Agreement with LEO Pharma 17

LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 18

Klox Technologies and LEO Pharma to Form Joint Venture 19

MorphoSys Expands Agreement with LEO Pharma 20

LEO Pharma Enters into Agreement with Washington University School of Medicine 21

Leo Pharma Enters into Distribution Agreement with NeoPharm 22

arGEN-X Enters into Co-Development Agreement with Leo Pharma 23

Fidelta Enters into Drug Discovery Agreement with LEO Pharma 24

Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 25

LEO Pharma And University of Queensland Enter Into Research Agreement For Skin Cancer 26

LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 27

LEO Pharma To Enter Into Joint Venture With Charite To Form I2DEAL 28

Zymeworks Enters into Research Collaboration and Licensing Agreement with LEO Pharma 29

LEO Pharma Enters into Licensing Agreement with JW Pharma 30

UTILITY therapeutics Enters into Licensing Agreement with LEO Pharma 31

LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 32

LEO Pharma Enters Into Licensing Agreement With AstraZeneca For Brodalumab 33

Leo Pharma Enters into Licensing Agreement with Japan Tobacco for JTE-052 34

LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 35

LEO Pharma Invests in Novopyxis 36

Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 37

Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 39

LEO Pharma A/S, Key Competitors 40

LEO Pharma A/S, Key Employees 41

LEO Pharma A/S, Subsidiaries 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS